282 related articles for article (PubMed ID: 12015321)
1. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor.
Masiello D; Cheng S; Bubley GJ; Lu ML; Balk SP
J Biol Chem; 2002 Jul; 277(29):26321-6. PubMed ID: 12015321
[TBL] [Abstract][Full Text] [Related]
2. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
Hodgson MC; Astapova I; Hollenberg AN; Balk SP
Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
[TBL] [Abstract][Full Text] [Related]
3. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
[TBL] [Abstract][Full Text] [Related]
4. Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells.
Shi XB; Xue L; Zou JX; Gandour-Edwards R; Chen H; deVere White RW
Prostate; 2008 Dec; 68(16):1816-26. PubMed ID: 18780293
[TBL] [Abstract][Full Text] [Related]
5. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
6. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor.
Kang Z; Jänne OA; Palvimo JJ
Mol Endocrinol; 2004 Nov; 18(11):2633-48. PubMed ID: 15308689
[TBL] [Abstract][Full Text] [Related]
7. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
[TBL] [Abstract][Full Text] [Related]
8. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
Koukourakis MI; Kakouratos C; Kalamida D; Mitrakas A; Pouliliou S; Xanthopoulou E; Papadopoulou E; Fasoulaki V; Giatromanolaki A
Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490
[TBL] [Abstract][Full Text] [Related]
10. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
[TBL] [Abstract][Full Text] [Related]
11. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.
Liu X; Gomez-Pinillos A; Liu X; Johnson EM; Ferrari AC
Prostate; 2010 Feb; 70(2):179-89. PubMed ID: 19790234
[TBL] [Abstract][Full Text] [Related]
12. Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes.
Dai Y; Ngo D; Jacob J; Forman LW; Faller DV
Carcinogenesis; 2008 Sep; 29(9):1725-33. PubMed ID: 18487222
[TBL] [Abstract][Full Text] [Related]
13. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
14. Antiandrogens prevent stable DNA-binding of the androgen receptor.
Farla P; Hersmus R; Trapman J; Houtsmuller AB
J Cell Sci; 2005 Sep; 118(Pt 18):4187-98. PubMed ID: 16141232
[TBL] [Abstract][Full Text] [Related]
15. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
[TBL] [Abstract][Full Text] [Related]
16. Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells.
Masiello D; Chen SY; Xu Y; Verhoeven MC; Choi E; Hollenberg AN; Balk SP
Mol Endocrinol; 2004 Oct; 18(10):2388-401. PubMed ID: 15256534
[TBL] [Abstract][Full Text] [Related]
17. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
Quéro L; Giocanti N; Hennequin C; Favaudon V
Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
[TBL] [Abstract][Full Text] [Related]
18. A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes.
Cherian MT; Wilson EM; Shapiro DJ
J Biol Chem; 2012 Jul; 287(28):23368-80. PubMed ID: 22589544
[TBL] [Abstract][Full Text] [Related]
19. Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex.
Kang Z; Pirskanen A; Jänne OA; Palvimo JJ
J Biol Chem; 2002 Dec; 277(50):48366-71. PubMed ID: 12376534
[TBL] [Abstract][Full Text] [Related]
20. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]